Pyridothienopyridazinone derivatives as mGluR1 antagonists
    6.
    发明授权
    Pyridothienopyridazinone derivatives as mGluR1 antagonists 失效
    吡啶并噻吩并哒嗪酮衍生物作为mGluR1拮抗剂

    公开(公告)号:US07687501B2

    公开(公告)日:2010-03-30

    申请号:US11505140

    申请日:2006-08-16

    CPC分类号: C07D487/22 C07D495/14

    摘要: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

    摘要翻译: 在其许多实施方案中,本发明提供用作代谢型谷氨酸受体(mGluR)拮抗剂的式I(其中J1-J3,X,Z和R1,R3和R4如本文所定义)的三环化合物,特别是作为选择性代谢型 谷氨酸受体1拮抗剂,含有该化合物的药物组合物,以及使用该化合物和组合物治疗与代谢型谷氨酸受体(例如,mGluR1)相关的疾病例如疼痛,偏头痛,焦虑症,尿失禁和神经变性疾病的治疗方法 这样的阿尔茨海默病。